185 related articles for article (PubMed ID: 35499071)
1. Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy.
Shurin MR; Umansky V
J Clin Invest; 2022 May; 132(9):. PubMed ID: 35499071
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
3. Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma.
Tawadros AIF; Khalafalla MMM
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1063-S1069. PubMed ID: 30539847
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
Noman MZ; Desantis G; Janji B; Hasmim M; Karray S; Dessen P; Bronte V; Chouaib S
J Exp Med; 2014 May; 211(5):781-90. PubMed ID: 24778419
[TBL] [Abstract][Full Text] [Related]
5. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
Eur J Cancer; 2016 Jun; 60():125-35. PubMed ID: 27107327
[TBL] [Abstract][Full Text] [Related]
6. HIF-1α inhibits T-2 toxin-mediated "immune evasion" process by negatively regulating PD-1/PD-L1.
You L; Wang X; Wu W; Nepovimova E; Wu Q; Kuca K
Toxicology; 2022 Oct; 480():153324. PubMed ID: 36115646
[TBL] [Abstract][Full Text] [Related]
7. Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues.
Bailey CM; Liu Y; Liu M; Du X; Devenport M; Zheng P; Liu Y; Wang Y
J Clin Invest; 2022 May; 132(9):. PubMed ID: 35239514
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
9. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
10. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Barsoum IB; Smallwood CA; Siemens DR; Graham CH
Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
[TBL] [Abstract][Full Text] [Related]
11. The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia.
Ding XC; Wang LL; Zhang XD; Xu JL; Li PF; Liang H; Zhang XB; Xie L; Zhou ZH; Yang J; Weichselbaum RR; Yu JM; Hu M
J Hematol Oncol; 2021 Jun; 14(1):92. PubMed ID: 34118979
[TBL] [Abstract][Full Text] [Related]
12. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
14. Deoxynivalenol upregulates hypoxia-inducible factor-1α to promote an "immune evasion" process by activating STAT3 signaling.
Zhang L; Wang X; Nepovimova E; Wu Q; Wu W; Kuca K
Food Chem Toxicol; 2023 Sep; 179():113975. PubMed ID: 37517547
[TBL] [Abstract][Full Text] [Related]
15. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
[TBL] [Abstract][Full Text] [Related]
16. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
17. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3.
Xing Y; Mi C; Wang Z; Zhang ZH; Li MY; Zuo HX; Wang JY; Jin X; Ma J
Pharmacol Res; 2018 Sep; 135():166-180. PubMed ID: 30103001
[TBL] [Abstract][Full Text] [Related]
18. The Tumor Microenvironment Mediates the HIF-1α/PD-L1 Pathway to Promote Immune Escape in Colorectal Cancer.
Sun J; Zhao Z; Lu J; An W; Zhang Y; Li W; Yang L
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612546
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicles derived from lung cancer cells exposed to intermittent hypoxia upregulate programmed death ligand 1 expression in macrophages.
Liu Y; Lu M; Chen J; Li S; Deng Y; Yang S; Ou Q; Li J; Gao P; Luo Z; Yuan P; Tan J; Gao X
Sleep Breath; 2022 Jun; 26(2):893-906. PubMed ID: 34254261
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.
Oh SA; Wu DC; Cheung J; Navarro A; Xiong H; Cubas R; Totpal K; Chiu H; Wu Y; Comps-Agrar L; Leader AM; Merad M; Roose-Germa M; Warming S; Yan M; Kim JM; Rutz S; Mellman I
Nat Cancer; 2020 Jul; 1(7):681-691. PubMed ID: 35122038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
